Chronic complications in patients with newly diagnosed type 2 diabetes: prevalence and related metabolic and clinical features: the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 9

Enzo Bonora, Maddalena Trombetta, Marco Dauriz, Daniela Travia, Vittorio Cacciatori, Corinna Brangani, Carlo Negri, Fabrizia Perrone, Isabella Pichiri, Vincenzo Stoico, Giacomo Zoppini, Elisabetta Rinaldi, Giuliana Da Prato, Maria Linda Boselli, Lorenza Santi, Federica Moschetta, Monica Zardini, Riccardo C Bonadonna, Enzo Bonora, Maddalena Trombetta, Marco Dauriz, Daniela Travia, Vittorio Cacciatori, Corinna Brangani, Carlo Negri, Fabrizia Perrone, Isabella Pichiri, Vincenzo Stoico, Giacomo Zoppini, Elisabetta Rinaldi, Giuliana Da Prato, Maria Linda Boselli, Lorenza Santi, Federica Moschetta, Monica Zardini, Riccardo C Bonadonna

Abstract

Introduction: We explored the presence of chronic complications in subjects with newly diagnosed type 2 diabetes referred to the Verona Diabetes Clinic. Metabolic (insulin secretion and sensitivity) and clinical features associated with complications were also investigated.

Research design and methods: The comprehensive assessment of microvascular and macrovascular complications included detailed medical history, resting ECG, ultrasonography of carotid and lower limb arteries, quantitative neurological evaluation, cardiovascular autonomic tests, ophthalmoscopy, kidney function tests. Insulin sensitivity and beta-cell function were assessed by state-of-the-art techniques (insulin clamp and mathematical modeling of glucose/C-peptide curves during oral glucose tolerance test).

Results: We examined 806 patients (median age years, two-thirds males), of whom prior clinical cardiovascular disease (CVD) was revealed in 11.2% and preclinical CVD in 7.7%. Somatic neuropathy was found in 21.2% and cardiovascular autonomic neuropathy in 18.6%. Retinopathy was observed in 4.9% (background 4.2%, proliferative 0.7%). Chronic kidney disease (estimated glomerular filtration rate <60 mL/min/1.73 m2) was found in 8.8% and excessive albuminuria in 13.2% (microalbuminuria 11.9%, macroalbuminuria 1.3%).Isolated microvascular disease occurred in 30.8%, isolated macrovascular disease in 9.3%, a combination of both in 9.1%, any complication in 49.2% and no complications in 50.8%.Gender, age, body mass index, smoking, hemoglobin A1c and/or hypertension were independently associated with one or more complications. Insulin resistance and beta-cell dysfunction were associated with macrovascular but not microvascular disease.

Conclusions: Despite a generally earlier diagnosis for an increased awareness of the disease, as many as ~50% of patients with newly diagnosed type 2 diabetes had clinical or preclinical manifestations of microvascular and/or macrovascular disease. Insulin resistance might play an independent role in macrovascular disease.

Trial registration number: NCT01526720.

Keywords: diabetes complications; diabetes mellitus; insulin resistance; insulin secretion; type 2.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993;16:642–52. 10.2337/diacare.16.4.642
    1. UKPDS Group UK prospective diabetes study 6. complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990;13:1–1111.
    1. Adler AI, Stevens RJ, Manley SE, et al. . Development and progression of nephropathy in type 2 diabetes: the United Kingdom prospective diabetes study (UKPDS 64). Kidney Int 2003;63:225–32. 10.1046/j.1523-1755.2003.00712.x
    1. Hillier TA, Pedula KL. Complications in young adults with early-onset type 2 diabetes: losing the relative protection of youth. Diabetes Care 2003;26:2999–3005. 10.2337/diacare.26.11.2999
    1. Looker HC, Nyangoma SO, Cromie D, et al. . Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 2012;55:2335–42. 10.1007/s00125-012-2596-z
    1. Kostev K, Rathmann W. Diabetic retinopathy at diagnosis of type 2 diabetes in the UK: a database analysis. Diabetologia 2013;56:109–11. 10.1007/s00125-012-2742-7
    1. Winkley K, Thomas SM, Sivaprasad S, et al. . The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London diabetes cohort (SOUL-D). Diabetologia 2013;56:1272–81. 10.1007/s00125-013-2873-5
    1. Kostev K, Jockwig A, Hallwachs A, et al. . Prevalence and risk factors of neuropathy in newly diagnosed type 2 diabetes in primary care practices: a retrospective database analysis in Germany and U.K. Prim Care Diabetes 2014;8:250–5. 10.1016/j.pcd.2014.01.011
    1. Piniés JA, González-Carril F, Arteagoitia JM, et al. . Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque country prospective complications and mortality study risk engine (BASCORE). Diabetologia 2014;57:2324–33. 10.1007/s00125-014-3370-1
    1. Sandbæk A, Griffin SJ, Sharp SJ, et al. . Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe study. Diabetes Care 2014;37:2015–23. 10.2337/dc13-1544
    1. Martinell M, Dorkhan M, Stålhammar J, et al. . Prevalence and risk factors for diabetic retinopathy at diagnosis (DRAD) in patients recently diagnosed with type 2 diabetes (T2D) or latent autoimmune diabetes in the adult (LADA). J Diabetes Complications 2016;30:1456–61. 10.1016/j.jdiacomp.2016.08.009
    1. Simmons RK, Griffin SJ, Lauritzen T, et al. . Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia 2017;60:2192–9. 10.1007/s00125-017-4299-y
    1. Christensen DH, Nicolaisen SK, Berencsi K, et al. . Danish centre for strategic research in type 2 diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile. BMJ Open 2018;8:e017273. 10.1136/bmjopen-2017-017273
    1. Gedebjerg A, Almdal TP, Berencsi K, et al. . Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: a cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. J Diabetes Complications 2018;32:34–40. 10.1016/j.jdiacomp.2017.09.010
    1. Ahlqvist E, Storm P, Käräjämäki A, et al. . Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 2018;6:361–9. 10.1016/S2213-8587(18)30051-2
    1. Zaharia OP, Strassburger K, Strom A, et al. . Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 2019;7:684–94. 10.1016/S2213-8587(19)30187-1
    1. Porta M, Curletto G, Cipullo D, et al. . Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care 2014;37:1668–74. 10.2337/dc13-2101
    1. Bonetti S, Trombetta M, Malerba G, et al. . Variants and haplotypes of TCF7L2 are associated with β-cell function in patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study (VNDS) 1. J Clin Endocrinol Metab 2011;96:E389–93. 10.1210/jc.2010-1677
    1. Bonetti S, Trombetta M, Boselli ML, et al. . Variants of GCKR affect both β-cell and kidney function in patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study 2. Diabetes Care 2011;34:1205–10. 10.2337/dc10-2218
    1. Trombetta M, Bonetti S, Boselli M, et al. . CACNA1E variants affect beta cell function in patients with newly diagnosed type 2 diabetes. The Verona newly diagnosed type 2 diabetes study (VNDS) 3. PLoS One 2012;7:e32755. 10.1371/journal.pone.0032755
    1. Trombetta M, Bonetti S, Boselli ML, et al. . PPARG2 Pro12Ala and ADAMTS9 rs4607103 as "insulin resistance loci" and "insulin secretion loci" in Italian individuals. The GENFIEV study and the Verona Newly Diagnosed Type 2 Diabetes Study (VNDS) 4. Acta Diabetol 2013;50:401–8. 10.1007/s00592-012-0443-9
    1. Trombetta M, Dauriz M, Bonetti S, et al. . Is common genetic variation at IRS1, ENPP1 and TRIB3 loci associated with cardiometabolic phenotypes in type 2 diabetes? an exploratory analysis of the Verona newly diagnosed type 2 diabetes study (VNDS) 5. Nutr Metab Cardiovasc Dis 2016;26:232–8. 10.1016/j.numecd.2016.01.002
    1. Zoppini G, Cacciatori V, Raimondo D, et al. . Prevalence of cardiovascular autonomic neuropathy in a cohort of patients with newly diagnosed type 2 diabetes: the Verona newly diagnosed type 2 diabetes study (VNDS). Diabetes Care 2015;38:1487–93. 10.2337/dc15-0081
    1. Epstein FH, Ostrander LD, JOHNSON BC, et al. . Epidemiological studies of cardiovascular disease in a total community--tecumseh, Michigan. Ann Intern Med 1965;62:1170–87. 10.7326/0003-4819-62-6-1170
    1. International Diabetes Federation IDF diabetes atlas. 8th Edition International Diabetes Federation, 2017.
    1. Levey AS, Bosch JP, Lewis JB, et al. . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease Study Group. Ann Intern Med 1999;130:461–70. 10.7326/0003-4819-130-6-199903160-00002
    1. Bonora E, Formentini G, Calcaterra F, et al. . HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona diabetes complications study. Diabetes Care 2002;25:1135–41. 10.2337/diacare.25.7.1135
    1. Bonora E, Kiechl S, Willeit J, et al. . Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population: the Bruneck study. Diabetes Care 2007;30:318–24. 10.2337/dc06-0919
    1. Roy Chowdhury S, Thomas RL, Dunseath GJ, et al. . Diabetic retinopathy in newly diagnosed subjects with type 2 diabetes mellitus: contribution of β-cell function. J Clin Endocrinol Metab 2016;101:572–80. 10.1210/jc.2015-2203
    1. Christensen DH, Knudsen ST, Gylfadottir SS, et al. . Metabolic factors, lifestyle habits, and possible polyneuropathy in early type 2 diabetes: a nationwide study of 5,249 patients in the Danish centre for strategic research in type 2 diabetes (DD2) cohort. Diabetes Care 2020;43:1266–75. 10.2337/dc19-2277
    1. Szwarcbard N, Villani M, Earnest A, et al. . The association of smoking status with glycemic control, metabolic profile and diabetic complications– results of the Australian National diabetes audit (ANDA). J Diabetes Complications 2020;34:107626 10.1016/j.jdiacomp.2020.107626
    1. Cerami C, Founds H, Nicholl I, et al. . Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 1997;94:13915–20. 10.1073/pnas.94.25.13915
    1. G SBA, Choi S, Krishnan J, et al. . Cigarette smoke and related risk factors in neurological disorders: an update. Biomed Pharmacother 2017;85:79–86. 10.1016/j.biopha.2016.11.118

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren